The Endocrine Society's Guidelines for the Pharmacologic Management of Obesity, advises clinicians to "treat weight first" to mitigate or eliminate its related comorbidities and complications including type 2 diabetes. Learn more about this dynamic program, the benefits of weight reduction on diabetes, and how to earn 1.5 AMA PRA Category 1 CME credits.
- Posted June 15, 2016 by Beta Cells in Diabetes Staff
- Posted August 4, 2014 by John L. Leahy, MD
Is there actually a proven benefit of intensive blood glucose control in patients who have diabetes, and if there is what actually is that benefit? In this 8-minute podcast, Drs. Jack Leahy and Doron Schneider answer this question based on data from The Diabetes Control and Complications study.
- Posted June 12, 2013 by John L. Leahy, MD
Doron Schneider, MD and Jack Leahy, MD discuss the importance of patient BMI and other risk factors for coronary artery disease when weighing treatment options.
- Posted May 29, 2013 by John L. Leahy, MD
Dr. Jack Leahy, endocrinologist and general internist, Dr. Doron Schneider, weigh different initial treatment options presented by leading endocrinologists Silvio Inzucchi, MD, Alan J. Garber, MD and Laurence Kennedy, MD
The Good, The Bad, and the Ugly Part II: Why I’m not a Fan of the ADA/EASD’s 2012 Position StatementPosted June 6, 2012 by John L. Leahy, MD
- Posted May 30, 2012 by John L. Leahy, MDThe highly awaited ADA/EASD statement on management of type 2 diabetes was published online April 19th, 2012.1 I feel like a curmudgeon,but as a general statement, I’m not a fan. In fact, I’m worried that at best it will have little impact, and at worst could be harmful.
- Posted March 28, 2012 by John L. Leahy, MD
In the past decade or so, our attempts to define the "earliest” events in Type 2 diabetes (T2DM) have moved increasingly earlier. We’re considering even the years before what we now consider to be the “pre-diabetes” stage—that is, years considerably before there are any clinical signs or symptoms of disease.
- Posted April 7, 2011 by Kim C. Dixon, MD
Fatty liver disease is the most common cause of chronic liver disease in North America and is becoming one of the top reasons for liver transplantation. Fatty liver causes inflammation that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. The physiologic relationship between type 2 diabetes mellitus and fatty liver disease is complex and multifactorial.
- Page 1 of 2